A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

Phase 2 Completed 360 enrolled BioLineRx, Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.

Timeline

Start: 2008-07
Primary completion: 2009-07
Completion: 2009-09

Publications

Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep;73(9):e1168-74. doi: 10.4088/JCP.12m07642.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PERPHENAZINE 4-AMINOBUTYRATE	Small molecule	10 mg	—
Subject	PERPHENAZINE 4-AMINOBUTYRATE	Small molecule	20 mg	—
Subject	PERPHENAZINE 4-AMINOBUTYRATE	Small molecule	30 mg	—
Comparator	Risperidone	Other / unclassified	2 mg	—
Comparator	Risperidone	Other / unclassified	8 mg	—

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

Summary

Timeline

Publications

Drugs

Indications